EUCTR2010-021394-37-IT进行中（未招募）不适用
STUDIO MULTICENTRICO, IN DOPPIO CIECO, CONTROLLATO VERSO PLACEBO, A GRUPPI PARALLELI, DI FASE IV VOLTO A VALUTARE GLI EFFETTI DELLA ROTIGOTINA NEI SINTOMI NON MOTORI IN SOGGETTI CON MALATTIA IDIOPATICA DI PARKINSON - SP0976
CB Pharma SA0 个研究点目标入组 345 人开始时间: 2011年12月28日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 345
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC)approved written Informed Consent form is signed and dated by the subject or legal representative. 2. Subject/legal representative is considered reliable and capable of adhering to the protocol, visit schedule and medication intake according to the judgment of the investigator. 3. Subject is male or female, = 18 years of age. 4. Subject has idiopathic Parkinson’s disease with at least two(2) or more of the following cardinal signs being present: bradykinesia, resting tremor, rigidity or postural instability, and without any other known or suspected cause of Parkinsonism. 5. Subject has a Hoehn and Yahr stage score = 4. 6. Subject has a total NMSS = 40 UCB Final 28Sep2010 Protocol Summary Rotigotine SP0976 Confidential Page 6 of 14 7. If the subject is receiving anticholinergics, monoamine oxidase B (MAO-B) or amantadine, he/she must have been on a stable dose for at least 28 days prior to the Baseline Visit and must be maintained on that dose for the duration of the trial. 8. If subject is taking levodopa (L-DOPA), he/she must be on a stable dose of L-DOPA (in combination with benserazide or carbidopa) for at least 28 days prior to the Baseline Visit. 9. Female subjects of childbearing potential must agree to practice an adequate contraception method.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subject has previously participated in this study or subject has previously been assigned to treatment in a study of the medication under investigation in this study. 2. Subject has participated in another study of an IMP within 30 days prior to the Screening Period or is currently participating in another study of an IMP. 3. Subject has a history of chronic alcohol or drug abuse within the previous year. 4. Subject has any medical, psychiatric, or cognitive condition that, in the opinion of the investigator, could jeopardize or would compromise the subject’s well being or ability to participate in this study. 5. Subject has a known hypersensitivity to any components of the IMP, including sodium metabisulfite. 6. Subject has a significant skin disease that would make transdermal drug use inappropriate, including a history of skin sensitivity to adhesives or transdermal medications. 7. Subject discontinued from previous therapy with a dopamine agonist after an adequate length of treatment, at an adequate dose, due to lack of efficacy as assessed by the investigator. 8. Subject is receiving therapy with 1 of the following drugs, either concurrently or within 28 days prior to the Baseline Visit: alpha-methyl dopa, metoclopramide, reserpine, neuroleptics (except specific atypical neuroleptics: olanzapine, ziprasidone, aripiprazole, clozapine, and quetiapine), MAO-A inhibitors, methylphenidate, amphetamine, or other dopamine agonists (DAs). 9. Subject is receiving central nervous system (CNS) therapy (eg, sedatives, hypnotics, selective serotonin reuptake inhibitors [SSRIs], anxiolytics, or other sleep-modifying medication) unless dose has been stable daily for at least 28 days prior to the Baseline Visit and is likely to remain stable for the duration of the study. 10. Subject has evidence of an ICD according to the mMIDI at the Screening Visit (Visit 1), confirmed by a positive structured clinical interview.
研究者
相似试验
已完成
不适用
Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus-E119 Non-insulin-dependent diabetes mellitus, without complicationsNon-insulin-dependent diabetes mellitus, without complicationsE119PER-032-04TAKEDA PHARMACEUTICALS,
进行中（未招募）
不适用
Estudio multicéntrico, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y seguridad de la teriflunomida en pacientes con esclerosis múltiple recurrente que están en tratamiento con interferón-beta____________A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - TERACLESEsclerosis múltiple_______Multiple sclerosisMedDRA version: 12.1Level: LLTClassification code 10028245Term: Multiple sclerosisEUCTR2010-023172-12-ESsanofi-aventis recherche et development1,455
进行中（未招募）
1 期
Estudio multicéntrico, doble ciego, controlado con placebo, de grupos paralelos, fase IV para evaluar el efecto de rotigotina sobre los síntomas no motores en pacientes con enfermedad de Parkinson idiopática(Multicenter, double-blind, placebo controlled, parallel-group, phase IV study to assess the effect of rotigotine on non-motor symptoms in patients with idiopathic parkinsons disease) - SP0976Enfermedad de ParkinsonMedDRA version: 12.1Level: LLTClassification code 10061536Term: Parkinson's diseaseEUCTR2010-021394-37-ESCB Pharma SA349
进行中（未招募）
不适用
Estudio multicéntrico, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y seguridad de teriflunomida en pacientes con esclerosis múltiple recurrente_________________________________________________________________A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis - TOWEREsclerosis múltiple_____________Multiple sclerosisMedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosisEUCTR2007-004452-36-ESSanofi-aventis recherche & développement1,110
进行中（未招募）
1 期
ESTUDIO DOBLE CIEGO, ALEATORIZADO Y CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA, LA SEGURIDAD Y LA FARMACODINAMIA DE AT1001 EN PACIENTES CON ENFERMEDAD DE FABRY Y MUTACIONES EN GLA SENSIBLES A AT1001.A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACODYNAMICS OF AT1001 IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS.Enfermedad de Fabry.Fabry Disease.MedDRA version: 12.0Level: LLTClassification code 10016016Term: Fabry's diseaseEUCTR2009-013459-31-ESAmicus Therapeutics, Inc.180